Don’t miss the latest developments in business and finance.

Home / Content / B2B Connect / Pharma / Zydus Cadila receives US FDA approval for anti-inflammatory drug budesonide

Zydus Cadila receives US FDA approval for anti-inflammatory drug budesonide

Budesonide is estimated to have annual sales of $ 285.8 million, according to IMS

Capsules; Image Courtesy: Siegfried
Premium
BS B2B Bureau Ahmedabad
Last Updated : May 05 2017 | 1:48 PM IST
Connect with us
Facebook IconLinkedIN Icon
The Ahmedabad-based Zydus Cadila has received the final approval from the US Food & Drug Administration (FDA) to market budesonide capsules, 3 mg (enteric coated). The drug is a corticosteroid used for its anti-inflammatory action.

Zydus Cadila will produce the approved drug at the group's formulation manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales of budesonide is $ 285.8 million (IMS MAT March 2017).

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Connect with us on WhatsApp

Also Read

Natco receives US FDA approval for generic budesonide capsule

Zydus Cadila receives US FDA approval for cholestyramine suspension

Zydus Cadila receives US FDA nod for anti-fungal drug fluconazole tablet

Zydus receives US FDA approval for anti-viral drug oseltamivir

Alembic Pharmaceuticals receives US FDA nod for hypertension drugs

First Published: May 05 2017 | 1:45 PM IST

Explore News